Sunshine Biopharma INC 8-K filings

Sunshine Biopharma's CEO, Dr. Steve Slilaty, purchased 100,000 shares of Series B Preferred Stock for $10,000 and approved a reverse stock split to regain Nasdaq compliance.

Sunshine Biopharma is appealing Nasdaq's decision to delist its stock after it traded below $0.10 for ten consecutive days, while also planning a 40-for-1 reverse stock split to regain compliance.

Sunshine Biopharma obtained shareholder consent to modify terms of its Series A and B warrants, including adjustments to exercise prices and cashless exercise options.

Sunshine Biopharma has successfully priced a $10 million underwritten public offering to fund general corporate purposes and working capital.

Sunshine Biopharma has repurchased and cancelled outstanding warrants from 2022 and 2023 for a total of $3,139,651, eliminating potential future dilution.

Sunshine Biopharma has appointed a new Chief Operating Officer and Chief Development Officer, while other executives retain their positions.